TY - JOUR
T1 - CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022
AU - The Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT)
AU - Ozaki, Yukio
AU - Hara, Hironori
AU - Onuma, Yoshinobu
AU - Katagiri, Yuki
AU - Amano, Tetsuya
AU - Kobayashi, Yoshio
AU - Muramatsu, Takashi
AU - Ishii, Hideki
AU - Kozuma, Ken
AU - Tanaka, Nobuhiro
AU - Matsuo, Hitoshi
AU - Uemura, Shiro
AU - Kadota, Kazushige
AU - Hikichi, Yutaka
AU - Tsujita, Kenichi
AU - Ako, Junya
AU - Nakagawa, Yoshihisa
AU - Morino, Yoshihiro
AU - Hamanaka, Ichiro
AU - Shiode, Nobuo
AU - Shite, Junya
AU - Honye, Junko
AU - Matsubara, Tetsuo
AU - Kawai, Kazuya
AU - Igarashi, Yasumi
AU - Okamura, Atsunori
AU - Ogawa, Takayuki
AU - Shibata, Yoshisato
AU - Tsuji, Takafumi
AU - Yajima, Junji
AU - Iwabuchi, Kaoru
AU - Komatsu, Nobuo
AU - Sugano, Teruyasu
AU - Yamaki, Masaru
AU - Yamada, Shinichiro
AU - Hirase, Hiroaki
AU - Miyashita, Yuusuke
AU - Yoshimachi, Fuminobu
AU - Kobayashi, Masakazu
AU - Aoki, Jiro
AU - Oda, Hirotaka
AU - Katahira, Yoshiaki
AU - Ueda, Kinzo
AU - Nishino, Masami
AU - Nakao, Koichi
AU - Michishita, Ichiro
AU - Ueno, Takafumi
AU - Inohara, Taku
AU - Kohsaka, Shun
AU - Ismail, Tevfik F.
AU - Serruys, Patrick W.
AU - Nakamura, Masato
AU - Yokoi, Hiroyoshi
AU - Ikari, Yuji
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/1
Y1 - 2022/1
N2 - Primary Percutaneous Coronary Intervention (PCI) has significantly contributed to reducing the mortality of patients with ST-segment elevation myocardial infarction (STEMI) even in cardiogenic shock and is now the standard of care in most of Japanese institutions. The Task Force on Primary PCI of the Japanese Association of Cardiovascular Interventional and Therapeutics (CVIT) society proposed an expert consensus document for the management of acute myocardial infarction (AMI) focusing on procedural aspects of primary PCI in 2018. Updated guidelines for the management of AMI were published by the European Society of Cardiology (ESC) in 2017 and 2020. Major changes in the guidelines for STEMI patients included: (1) radial access and drug-eluting stents (DES) over bare-metal stents (BMS) were recommended as a Class I indication, (2) complete revascularization before hospital discharge (either immediate or staged) is now considered as Class IIa recommendation. In 2020, updated guidelines for Non-ST-Elevation Myocardial Infarction (NSTEMI) patients, the followings were changed: (1) an early invasive strategy within 24 h is recommended in patients with NSTEMI as a Class I indication, (2) complete revascularization in NSTEMI patients without cardiogenic shock is considered as Class IIa recommendation, and (3) in patients with atrial fibrillation following a short period of triple antithrombotic therapy, dual antithrombotic therapy (e.g., DOAC and single oral antiplatelet agent preferably clopidogrel) is recommended, with discontinuation of the antiplatelet agent after 6 to 12 months. Furthermore, an aspirin-free strategy after PCI has been investigated in several trials those have started to show the safety and efficacy. The Task Force on Primary PCI of the CVIT group has now proposed the updated expert consensus document for the management of AMI focusing on procedural aspects of primary PCI in 2022 version.
AB - Primary Percutaneous Coronary Intervention (PCI) has significantly contributed to reducing the mortality of patients with ST-segment elevation myocardial infarction (STEMI) even in cardiogenic shock and is now the standard of care in most of Japanese institutions. The Task Force on Primary PCI of the Japanese Association of Cardiovascular Interventional and Therapeutics (CVIT) society proposed an expert consensus document for the management of acute myocardial infarction (AMI) focusing on procedural aspects of primary PCI in 2018. Updated guidelines for the management of AMI were published by the European Society of Cardiology (ESC) in 2017 and 2020. Major changes in the guidelines for STEMI patients included: (1) radial access and drug-eluting stents (DES) over bare-metal stents (BMS) were recommended as a Class I indication, (2) complete revascularization before hospital discharge (either immediate or staged) is now considered as Class IIa recommendation. In 2020, updated guidelines for Non-ST-Elevation Myocardial Infarction (NSTEMI) patients, the followings were changed: (1) an early invasive strategy within 24 h is recommended in patients with NSTEMI as a Class I indication, (2) complete revascularization in NSTEMI patients without cardiogenic shock is considered as Class IIa recommendation, and (3) in patients with atrial fibrillation following a short period of triple antithrombotic therapy, dual antithrombotic therapy (e.g., DOAC and single oral antiplatelet agent preferably clopidogrel) is recommended, with discontinuation of the antiplatelet agent after 6 to 12 months. Furthermore, an aspirin-free strategy after PCI has been investigated in several trials those have started to show the safety and efficacy. The Task Force on Primary PCI of the CVIT group has now proposed the updated expert consensus document for the management of AMI focusing on procedural aspects of primary PCI in 2022 version.
KW - Dual antiplatelet therapy (DAPT)
KW - Non-ST-segment elevation acute coronarysyndrome (NSTE-ACS)
KW - Percutaneous coronary intervention (PCI)
KW - ST-segment elevation acute myocardial infarction (STEMI)
KW - Thrombus aspiration, Optical coherencetomography (OCT)
UR - https://www.scopus.com/pages/publications/85122827259
U2 - 10.1007/s12928-021-00829-9
DO - 10.1007/s12928-021-00829-9
M3 - Review article
C2 - 35018605
AN - SCOPUS:85122827259
SN - 1868-4300
VL - 37
JO - Cardiovascular Intervention and Therapeutics
JF - Cardiovascular Intervention and Therapeutics
IS - 1
ER -
SDG 3 Good Health and Well-being